Dr. Hunter is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
150 Stephen P Yokich Pkwy
Suite H
Spring Hill, TN 37174Phone+1 615-791-5470Fax+1 615-595-0265
Education & Training
- Mayo Clinic College of Medicine and ScienceFellowship, Clinician Investigator Training Program, 1995 - 1997
- Mayo Clinic College of Medicine and Science (Rochester)Residency, Neurology, 1992 - 1995
- Mayo Clinic College of Medicine and Science (Rochester)Internship, Internal Medicine, 1991 - 1992
- University of Texas Medical Branch GalvestonPhD, Pharmacology-Toxicology, 1984 - 1991
- University of Texas Medical Branch School of MedicineClass of 1991
- University of Helsinkipostgraduate, Pharmacology/Physiology, ITT International Fellow/Flubright Award, 1983 - 1984
- Oral Roberts UniversityBS, Biology, Computer Science, Mathematics, Chemistry, Summa Cum Laude, 1979 - 1983
Certifications & Licensure
- TN State Medical License 1997 - 2025
- FL State Medical License 2015 - 2017
- TX State Medical License 1993 - 1998
- MN State Medical License 1992 - 1997
- American Board of Psychiatry and Neurology Neurology
Clinical Trials
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
- Immunodeficiency in MS Start of enrollment: 2020 Jun 29
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 22 citationsImpact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.Samuel F. Hunter, Mark Agius, Deborah M. Miller, Gary Cutter, Luigi Barbato
Journal of the Neurological Sciences. 2016-06-15 - 69 citationsOutcomes of switching directly to oral fingolimod from injectable therapies: Results of the randomized, open-label, multicenter, Evaluate Patient OutComes (EPOC) study...Edward Fox, Keith R. Edwards, Gordon Burch, Daniel Wynn, Chris LaGanke
Multiple Sclerosis and Related Disorders. 2014-09-01 - 20 citationsEfficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study.Sibyl Wray, Florian Then Bergh, Annette Wundes, Douglas L Arnold, Jelena Drulovic
Advances in Therapy. 2022-04-01
Press Mentions
- Preparing for #ACTRIMS2017 – Top 3 Topics from ACTRIMS 2016April 26th, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: